Russian Federation

China’s Bio-Thera Solutions and Russia’s Pharmapark have struck a deal to expand their existing biosimilars collaboration for Russia and the Commonwealth of Independent States with a further candidate: the Chinese firm’s BAT2306 proposed secukinumab biosimilar to Cosentyx.

With the war in Ukraine now in its third gruelling year, Stada has announced that it last year siphoned off its Russian interests to its parent company Nidda in a non-cash deal.

Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.

A sharp upswing in the US business, an alliance with Mark Cuban’s venture and a buoyant outlook in markets like China augur well for Dr Reddy’s. Can the company sustain momentum for the rest of year?  

Ninth Circuit overturns federal district court jury’s verdict dismissing Global Master Corp.’s complaint alleging Esmond Natural violated RICO Act by providing supplements of lower strength or otherwise different from products Global Master agreed to buy in US and distribute in China.

A sharp upswing in the US business, an alliance with Mark Cuban’s venture and a buoyant outlook in markets like China augur well for Dr Reddy’s. Can the company sustain momentum for the rest of year?

The second half of 2022 confirmed the slump in clinical trial activity in Russia that was seen in the first half of the year following the country's decision to invade Ukraine, and many of the trials approved that year are not expected to go ahead.

Slovenia’s Krka enjoyed a solid year for its dominant Prescription Pharmaceuticals business, with sales climbing by 7% on the back of growth for all six of its geographic business units.

On the anniversary of Russia’s invasion of Ukraine, the generics industry reflects on its contributions to relief efforts as well as the impact that the war has had on the supply chain.

China’s Mabwell has furthered its strategy to bring its biosimilars to global markets “for the benefit of millions of patients around the world” via a licensing agreement with Russian player Binnopharm.

The agency said it doesn't have the authority to consider sponsor’s country of origin when determining whether to act on applications, but reiterated that it continues to support Ukraine.

The Russian clinical trials organization ACTO says the “gloomy” prospects for multinational clinical trials in the country have led many sponsors to postpone the initiation of new studies or abandon them entirely in favor of other markets.

Agency tells former OOPD director Tim Coté it doesn't have the authority to consider sponsor’s country of origin when determining whether to act on applications. Despite the denial of petition, FDA continues to support Ukraine.

The agency tells former OOPD Director Tim Coté that it does not have the authority to consider the sponsor’s country of origin when determining whether to act on an application.

Ukraine’s medical supply needs have evolved since Russia launched its military invasion of the country on 24 February. EU healthcare decision makers and the medical technology industry have since stood firm in their support of the besieged country, said MedTech Europe’s Jesús Rueda.

Ukraine’s medical supply needs have evolved since Russia launched its military invasion of the country on 24 February. EU healthcare decision makers and the medical technology industry have stood firm in their support of the besieged country, said MedTech Europe’s Jesús Rueda.

Russia and Ukraine had been key players in the pharma markets of Central Asian and surrounding countries before the launch of the Russian invasion into its neighbor on 24 February. Because of this, both countries are poised to give ground in this growing regional market.

Pharmaceutical leaders are responding to the many and varied challenges arising from the war in Ukraine.  

Slovenia’s Krka surprised the market with nearly 10% group turnover growth in the first quarter, driven by increases in all six of its sales regions, “most key markets, and by all product and service groups.”

Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?